S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), executed significant stock transactions on March 10, 2025, as detailed in a recent SEC filing. Dickinson sold a total of 17,929 shares, yielding approximately $2.1 million. The sale prices ranged from $117.30 to $118.50 per share, near the stock’s 52-week high of $119.96. According to InvestingPro analysis, Gilead’s stock has delivered an impressive 58% return over the past year.
In addition to the sales, Dickinson acquired shares through options exercises. He exercised options to acquire 17,929 shares at a price of $63.91 per share, totaling approximately $1.15 million, under a 10b5-1 trading plan adopted in August 2024. These transactions are part of a broader management strategy and reflect ongoing adjustments to his equity holdings in the company. InvestingPro data shows Gilead maintains a GREAT financial health score, with notably low price volatility (Beta: 0.24).
Following these transactions, Dickinson’s direct ownership of Gilead’s common stock was adjusted to 169,061 shares. The stock transactions were executed as part of a pre-established trading plan, ensuring compliance with regulatory requirements. With a market capitalization of $142 billion, Gilead appears fairly valued according to InvestingPro Fair Value metrics. InvestingPro subscribers have access to 16 additional key insights about Gilead’s financial outlook and comprehensive Pro Research Reports.
In other recent news, Gilead Sciences has reported significant advancements in its HIV treatment and prevention portfolio. At the 2025 Conference on Retroviruses and Opportunistic Infections, the company showcased high efficacy data from its Phase 3 study on Biktarvy, which demonstrated strong viral suppression rates in HIV and HBV co-infected patients. Additionally, Gilead’s investigational treatment regimen combining lenacapavir with broadly neutralizing antibodies met its primary endpoint in a Phase 2 study, earning Breakthrough Therapy Designation from the FDA. In related developments, Bernstein analysts reiterated an Outperform rating for Gilead, maintaining a $120 price target, citing the promising potential of the company’s HIV preventative treatment, Len for PrEP.
Oppenheimer analysts have also increased their price target for Gilead to $132, driven by optimistic projections for the cancer drug Trodelvy. The drug, which is under evaluation in the ASCENT-03 trial, is expected to significantly impact Gilead’s sales, particularly in the treatment of triple-negative breast cancer. In executive news, Gilead announced the departure of Sandra Patterson, its Senior Vice President, Corporate Controller, and Chief Accounting Officer, with Diane E. Wilfong appointed as her interim successor. These recent developments highlight Gilead’s ongoing efforts to innovate in the fields of HIV treatment and prevention, as well as its strategic focus on expanding its oncology portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.